Palbociclib in combination with letrozole in patients with Hormone Receptor-positive/HER2-negative residual disease after standard neoadjuvant chemotherapy
PROMETEO II
Window Program
Palbociclib in combination with letrozole in patients with Hormone Receptor-positive/HER2-negative residual disease after standard neoadjuvant chemotherapy
Phase 0
Status
Follow up
Tumour subtype:
HR+
Scenario
Neoadyuvante
Sites
HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL SON ESPASES, HOSPITAL UNIVERSITARI GENERAL DE CATALUNYA, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO INFANTA SOFIA SAN SEBASTIAN DE LOS REYES, HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO HOSPITALET (DURAN I REYNALS)
